KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Non-Current Assets for 16 consecutive years, with $915.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 3.07% year-over-year to $915.7 million, compared with a TTM value of $3.7 billion through Dec 2025, up 6.22%, and an annual FY2025 reading of $915.7 million, down 3.07% over the prior year.
  • Non-Current Assets was $915.7 million for Q4 2025 at Alnylam Pharmaceuticals, up from $898.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $945.6 million in Q1 2025 and bottomed at $784.3 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $859.1 million, with a median of $850.3 million recorded in 2023.
  • The sharpest move saw Non-Current Assets plummeted 35.39% in 2021, then increased 13.13% in 2025.
  • Year by year, Non-Current Assets stood at $834.7 million in 2021, then rose by 2.32% to $854.1 million in 2022, then fell by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then fell by 3.07% to $915.7 million in 2025.
  • Business Quant data shows Non-Current Assets for ALNY at $915.7 million in Q4 2025, $898.9 million in Q3 2025, and $922.3 million in Q2 2025.